Europe Glioblastoma Multiforme Treatment Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$801.5

Forecast, 2030 (US$M)

$1.0

CAGR, 2024 - 2030

-61.5%

Report Coverage

Europe

Europe glioblastoma multiforme treatment market, 2018-2030 (US$M)

Related Markets

Global Glioblastoma Multiforme Treatment Industry Outlook

North America Glioblastoma Multiforme Treatment Market Outlook

Asia Pacific Glioblastoma Multiforme Treatment Market Outlook

Latin America Glioblastoma Multiforme Treatment Market Outlook

MEA Glioblastoma Multiforme Treatment Market Outlook

Europe glioblastoma multiforme treatment market highlights

The Europe glioblastoma multiforme treatment market generated a revenue of USD 801.5 million in 2023.
The market is expected to grow at a CAGR of -61.5% from 2024 to 2030.
In terms of segment, hospitals was the largest revenue generating end-use in 2023.
Hospitals is the most lucrative end-use segment registering the fastest growth during the forecast period.

Europe data book summary

Market revenue in 2023	USD 801.5 million
Market revenue in 2030	USD 1.0 million
Growth rate	-61.5% (CAGR from 2023 to 2030)
Largest segment	Hospitals
Fastest growing segment	Hospitals
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Hospitals
Key market players worldwide	Merck & Co Inc, Amgen Inc, Roche, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries, Arbor Pharmaceuticals, Amneal Pharmaceuticals, Karyopharm Therapeutics Inc, Sumitomo Dainippon Pharma Oncology

Other key industry trends

In terms of revenue, Europe region accounted for 52.9% of the global glioblastoma multiforme treatment market in 2023.
Globally, Latin America is projected to lead the regional market in terms of revenue in 2030.
North America is the fastest growing regional market and is projected to reach USD 2.0 million by 2030.

Key Regions: UK , U.S. , Japan , Brazil , UAE

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Glioblastoma Multiforme Treatment Market Scope

Glioblastoma multiforme treatment market segmentation & scope

End-Use

Hospitals

Clinics

Ambulatory Surgical Centers

Treatment

Surgery

Radiation therapy

Chemotherapy

Targeted Therapy

Tumor Treating Field (TTF) Therapy

Immunotherapy

Regions

Europe

Countries

U.S.

Canada

Germany

France

Italy

Spain

Switzerland

Netherlands

Denmark

Sweden

Norway

Japan

China

India

Mexico

Brazil

South Africa

Saudi Arabia

Argentina

UAE

Kuwait

Glioblastoma Multiforme Treatment Market Companies

Name	Profile	# Employees	HQ	Website

Europe glioblastoma multiforme treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.

Hospitals was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Europe glioblastoma multiforme treatment market based on hospitals covering the revenue growth of each sub-segment from 2018 to 2030.

Europe held 30.25% share of Glioblastoma Multiforme (GBM) treatment market in 2020. Its growth can be attributed to consistent initiatives being undertaken by organizations, such as the NHS, European Organization for Research and Treatment of Cancer, and European Association of Neuro-Oncology: EANO.

The standard GBM treatment in Europe is surgery, followed by radiation + chemotherapy (Temozolomide and other off-label drugs). The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) declined to approve the only targeted therapy Avastin (bevacizumab) due to low efficacy of the product, which was unable to outweigh its risk..

Reasons to subscribe to Europe glioblastoma multiforme treatment market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe glioblastoma multiforme treatment market databook

Our clientele includes a mix of glioblastoma multiforme treatment market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe glioblastoma multiforme treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list